Search Results - marc+ostermeier

3 Results

Sort By:

Efficient, Expansive, User-defined DNA Mutagenesis

C12015: Efficient, Expansive, User-defined DNA MutagenesisNovelty: This invention provides a leap forward in saturation mutagenesis called PFunkel. PFunkel is a next-generation Kunkel mutagenesis strategy that can, for the first time, efficiently and cheaply produce libraries containing user-defined mutations, including sequentially permuted genes....

Published: 3/13/2025 | Inventor(s): Elad Firnberg, Marc Ostermeier

Keywords(s): Basic Research Biomarker, Discovery/Research Tools, In Vitro Research Tool, Know-how

Category(s): Technology Classifications > Research Tools

Molecular Switches and Methods for Making and Using the Same Involving the Circular Permutation of DNA

Technical Details: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide...

Published: 3/13/2025 | Inventor(s): Gurkan Guntas, Marc Ostermeier

Keywords(s): Basic Research Biomarker, Cell Signaling, Discovery/Research Tools, Gene Therapy, Molecular Switches/Receptors, Research Reagent, Single, Therapeutic Matter, Therapeutic Substance Synthesis Method, Therapeutics, Therapy Type

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Gene Therapies

Selective Prodrug Activation in Cancer Cells Using Protein Switches

Unmet Need: Gene-directed enzyme prodrug therapy (GDEPT; also known as “suicide gene therapy”) is an emerging gene therapy strategy against cancer. A prodrug is systemically administered but only activated in cancer cells that have previously been modified to express an enzyme capable of activating the drug. Yet, the clinical utility of GDEPT to date...

Published: 3/13/2025 | Inventor(s): Chapman Wright, Marc Ostermeier

Keywords(s): Biologics, Biomarker, Cancers, Disease Indication, Gene Therapy, Mechanism-of-action Biomarker, Polypeptide, Protein, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type